Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients

Swiss Medical Weekly

Volumn 132, Issue 31-32, 2002, Pages 455-458

  Speich, Rudolf ^a   Dutly, André ^a   Naef, Rahel ^a   Russi, Erich W ^a   Weder, Walter ^a   Boehler, Annette ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Amphotericin B; Fungal infections; Lung transplant recipients

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; CYCLOSPORIN A; FUROSEMIDE; GANCICLOVIR; SODIUM CHLORIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDIASIS; CHILL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HEADACHE; HEMOFILTRATION; HUMAN; HYPOKALEMIA; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MYCOSIS; NEPHROTOXICITY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; RECIPIENT; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS INFECTION; VOMITING;

EID: 0037055914     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Nicod LP, Pache JC, Howarth N. Fungal infections in transplant recipients. Eur Respir J 2001;17:133-40.
2. Speich R, van Der Bij W. Epidemiology and management of infections after lung transplantation. Clin Infect Dis 2001;33: S58-65.
3. Kanj SS, Welty-Wolf K, Madden J, Tapson V, Baz MA, Davis RD, Perfect JR. Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine (Baltimore) 1996;75:142-56.
4. Palmer SM, Perfect JR, Howell DN, Lawrence CM, Miralles AP, Davis RD, Tapson VF. Candidal anastomotic infection in lung transplant recipients: Successful treatment with a combination of systemic and inhaled antifungal agents. J Heart Lung Transplant 1998;17:1029-33.
5. Grossi P, Farina C, Fiocchi R, Dalla Gasperina D. Prevalence and outcome of invasive fungal infections in 1963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000;70:112-6.
6. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26:781-803.
7. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. Br Med J 2001;322:579-82.
8. Speich R, Boehler A, Zalunardo M, Stocker R, Russi EW, Weder W. Improved results after lung transplantation - Analysis of factors. Swiss Med Wkly 2001;131:238-45.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
10. Mannes GP, van der Bij W, de Boer WJ, Ringden O, Andstrom E, Remberger M, et al. Liposomal amphotericin B in three lung transplant recipients. The Groningen Lung Transplantation Group. J Heart Lung Transplant 1995;14:781-4.
11. Ringden O, Andstrom E, Remberger M, Svahn BM, Tollemar J. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant 1994;14:S10-4.
12. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-71.